Nadroparin calcium

S

Calcinosis cutis at the application site: case report

A 63-year-old woman developed calcinosis cutis at the application site while receiving nadroparin calcium [Fraxiparin].

The woman was receiving chronic haemodialysis for polycystic kidney disease, and had advanced secondary hyperparathyroidism. She started receiving SC nadroparin calcium 2500IU on dialysis days and 2 × 2500IU on days without dialysis. She developed burning, itching and redness at the application site 3 days after her first injection of nadroparin calcium; nodular, erythematous, painful subcutaneous nodules developed with secondary infection and local necrosis. An x-ray of her upper arm showed clustered amorphous calcifications at application sites where nadroparin calcium had been administered. Following a biopsy, she was diagnosed with calcinosis cutis.

Nadroparin calcium was discontinued; the woman received aluminium hydroxide for 1 month and her dialysis treatment was adjusted. Local findings improved significantly after 1 month.

Author comment: "*In our case, it is possible that uncontrolled hyperparathyroidism and abnormal Ca/P metabolism as well as disruption of the local microarchitecture using subcutaneous injections of a heparin-calcium salt induced precipitation of calcium.*"

Bulatovic A, et al. Iatrogenic calcinosis cutis after subcutaneous LMW-heparin administration in a hemodialysis patient. International Urology and Nephrology 45: 1239-1241, No. 4, Aug 2013. Available from: URL: http://dx.doi.org/10.1007/s11255-013-0433-z - Serbia

803093161